Guardant Health Reports Results of Blood-Only Liquid Biopsy Test Predicting Risk of Colorectal Cancer Recurrence

May 3, 2021 Auto Bot colorectal cancer, Guardant Health, MedTech 0

Shots:

  • The study evaluates the effectiveness of the Guardant Reveal liquid biopsy test to detect MRD in patients with stage I-IV colorectal cancer after curative intent therapy
  • The blood samples were taken from intent population within 1mos. after treatment completion and in the subset of patients with clinical follow-up of 1yr, all patients with detectable ctDNA recurred. Guardant Reveal test sensitivity & specificity (55.6% & 100%) respectively for this single timepoint
  • The new test showed 91% sensitivity in detecting ctDNA by examining both genomic & epigenomic alterations of longitudinal surveillance samples

Click here to­ read full press release/ article | Ref: Businesswire | Image: Guardant

The post Guardant Health Reports Results of Blood-Only Liquid Biopsy Test Predicting Risk of Colorectal Cancer Recurrence first appeared on PharmaShots.